Pharmaceutical

Vorolanib by EyePoint Pharmaceuticals for Diabetic Macular Edema: Likelihood of Approval

Vorolanib is under clinical development by EyePoint Pharmaceuticals and currently in Phase II for Diabetic Macular Edema.

Feb 8, 2024 - 18:00
Vorolanib is under clinical development by EyePoint Pharmaceuticals and currently in Phase II for Diabetic Macular Edema.
Read the original article

Tags:

Previous Article

Monoclonal Antibody Conjugate 3 to Target EGFR for Oncology by ImmunityBio for N...

Next Article

Tapotoclax by Amgen for Chronic Myelomonocytic Leukemia (CMML): Likelihood of Ap...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Rare-disease doctors support expanded newborn genomic screening, survey finds

Rare-disease doctors support expanded newborn genomic s...

May 9, 2023

Developing high-potent APIs: The necessary steps to follow

Developing high-potent APIs: The necessary steps to follow

Aug 7, 2024

Eloxx moves ahead with plans with gene therapy for rare kidney disorder

Eloxx moves ahead with plans with gene therapy for rare...

Sep 9, 2023